Seung-Mi Lee

Incidence and treatment costs attributable to medication errors in hospitalized patients.

BACKGROUND A significant financial burden arises from medication errors that cause direct injury and those without patient harm that represent waste and inefficiency. OBJECTIVE To estimate the incidence, types, and causes of medication errors as well as their attributable costs in a hospital setting. METHODS For a retrospective case-control study, data were collected for 57,554 patients admitted to two New Jersey (U.S. State) hospitals during 2005-2006 as well as hospital-specific voluntary error reports from these two hospitals for the same period. Medication errors were classified into categories of stage, error type, and proximal cause, and the incidence was estimated. The costs attributable to medication errors were calculated using both the recycled prediction method, and the Blinder-Oaxaca decomposition method after propensity score matching. RESULTS Medication errors occurred at a rate of 0.8 per 100 admissions, or 1.6 per 1000 patient days. Most errors occurred at the administration stage of the medication use process. The most frequent types of errors were wrong time, wrong medication, wrong dose, and omission errors. Treatment costs attributable to medication errors were in the range of

Costs Attributable to Overweight and Obesity in Working Asthma Patients in the United States

8,439 using the Blinder-Oaxaca decomposition method and

The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study

8,898 using the recycled prediction method. CONCLUSIONS Medication errors are associated with significant additional costs, even without patient harm. Considering the substantial costs associated with adverse drug events, the elimination of medication errors should be further emphasized and promoted, and guidelines should be developed to facilitate this goal.

Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease

Purpose To estimate annual health care and productivity loss costs attributable to overweight or obesity in working asthmatic patients. Materials and Methods This study was conducted using the 2003–2013 Medical Expenditure Panel Survey (MEPS) in the United States. Patients aged 18 to 64 years with asthma were identified via self-reported diagnosis, a Clinical Classification Code of 128, or a ICD-9-CM code of 493.xx. All-cause health care costs were estimated using a generalized linear model with a log function and a gamma distribution. Productivity loss costs were estimated in relation to hourly wages and missed work days, and a two-part model was used to adjust for patients with zero costs. To estimate the costs attributable to overweight or obesity in asthma patients, costs were estimated by the recycled prediction method. Results Among 11670 working patients with a diagnosis of asthma, 4428 (35.2%) were obese and 3761 (33.0%) were overweight. The health care costs attributable to obesity and overweight in working asthma patients were estimated to be

Mediation effects of medication information processing and adherence on association between health literacy and quality of life

878 [95% confidence interval (CI):

Impact Of Adverse Drug Events On Hospital Length Of Stay And Hospitalization Costs In Hospitals For 2003-2009 In The United States

861–

Prevalence and predictors of non-steroidal anti-inflammatory drug/analgesic therapeutic duplication in the South Korean ambulatory care setting

895] and

Productivity Loss Costs Attributable to Obesity in Working Patients with Diabetes in the US

257 (95% CI:

Impact of warfarin discharge education program on hospital readmission and treatment costs

251–

Physicians’ and pharmacists’ perceptions on real-time drug utilization review system: a nationwide survey

262) per person per year, respectively, from 2003 to 2013. The productivity loss costs attributable to obesity and overweight among working asthma patients were